Weekly paclitaxel in the treatment of recurrent ovarian carcinoma

European Journal of Gynaecological Oncology

Volumn 28, Issue 3, 2007, Pages 174-178

  Byrd, L ^a   Thistlethwaite, F C ^a   Clamp, A ^a   Ton, C ^a   Hasan, J ^a   Jayson, G C ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Paclitaxel; Recurrent ovarian carcinoma; Recurrent peritoneal carcinoma

Indexed keywords

CA 125 ANTIGEN; DEXAMETHASONE; ONDANSETRON; PACLITAXEL; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CENTER; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOTENSION; KAPLAN MEIER METHOD; LETHARGY; LEUKOPENIA; NAUSEA; NEUROPATHY; OVARY CARCINOMA; PERITONEUM CANCER; RASH; RECURRENT CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34250845057     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Klauber N.: "Mortality Statistics cause. Review of the Registrar General on deaths by cause, sex and age, in England and Wales 2000". Series DH2 no 27. 2001.
2. Silverberg E., Boring C.C., Squires T.S.: "Cancer statistics, 1990". CA Cancer J. Clin., 1990, 40, 9.
3. Manfredi J.J., Horwitz S.B.: "Taxol: an antimitotic agent with a new mechanism of action". Pharmacol Ther., 1984, 25, 83.
4. Raymond E., Hanauske A., Faivre S., Izbicka E., Clark G., Rowinsky E.K. et al.: "Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units". Anticancer Drugs., 1997, 8, 379.
5. Lopes N.M., Adams E.G., Pitts T.W., Bhuyan B.K.: "Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines". Cancer Chemother. Pharmacol., 1993, 32, 235.
6. Georgiadis M.S., Russell E.K., Gazdar A.F., Johnson B.E.: "Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations". Clin. Cancer Res., 1997, 3, 449.
7. Saunders D.E., Lawrence W.D., Christensen C., Wappler N.L., Ruan H., Deppe G.: "Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells". Int. J. Cancer, 1997, 70, 214.
8. Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R.J.: "Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol". Cancer Res., 1997, 57, 81.
9. Kerbel R.S., Klement G., Pritchard K.I., Kamen B.: "Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic". Ann. Oncol., 2002 13, 12.
10. Marchetti P., Urien S., Cappellini G.A., Ronzino G., Ficorella C.: "Weekly administration of paclitaxel: theoretical and clinical basis". Crit. Rev. Oncol. Hematol., 2002, 44 (suppl.), S3.
11. McGuire W.P., Rowinsky E.K., Rosenshein N.B., Grumbine F.C., Ettinger D.S., Armstrong D.K. et al.: "Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms". Ann. Intern. Med., 1989, 111, 273.
12. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E. et al.: "Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results". J. Natl. Cancer Inst., 2000, 92, 699.
13. Rustin G.J.: "Can we now agree to use the same definition to measure response according to CA-125?". J. Clin. Oncol., 2004, 22, 4035.
14. Amendola M.A., Walsh J.W., Amendola B.E., Tisnado J., Hall D.J., Goplerud D.R.: "Computed tomography in the evaluation of carcinoma of the ovary". J. Comput. Assist. Tomogr., 1981, 5, 179.
15. Fennelly D., Aghajanian C., Shapiro F., O'Flaherty C., McKenzie M., O'Connor C. et al.: "Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer". J. Clin. Oncol., 1997, 15, 187.
16. Abu-Rustum N.R., Aghajanian C., Barakat R.R., Fennelly D., Shapiro F., Spriggs D.: "Salvage weekly paclitaxel in recurrent ovarian cancer". Semin Oncol., 1997, 24 (5 suppl. 15), S15.
17. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study". Gynecol. Oncol., 2006, 101, 436.
18. Miller K.D., Sweeney C.J., Sledge G.W. Jr.: "Redefining the target: chemotherapeutics as antiangiogenics". J. Clin. Oncol., 2001, 19, 1195.
19. Perez E.A., Vogel C.L., Irwin D.H., Kirshner J.J., Patel R.: "Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer". J. Clin. Oncol., 2001, 19, 4216.
20. Quock J., Dea G., Tanaka M., Gandara D., Lara P., Lau D.: "Pre-medication strategy for weekly paclitaxel". Cancer Invest., 2002, 20, 666.
21. Kita T., Kikuchi Y., Takano M., Suzuki M., Oowada M., Konno R., et al.: "The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer". Gynecol. Oncol., 2004, 92, 813.